Price
$496.07+16.07%Social Signal Score
Analyst Ratings
56 analystsRevenue
$3.44B+650.11%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Reshma Kewalramani
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6,400
- Beta
- 0.32
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 8.43
Financials
Revenue
$3.44B+650.1%Net Income
$653.60M+1883.9%EBITDA
$819.40M+1358.1%Free Cash Flow
$545.80M+320.1%EPS (diluted)
$2.56+1869.2%Shares Outstanding (diluted)
255.20M+3.0%Operating Expenses
$2.16BCash & Debt
$6.30BReturn of Capital
$126.70MRevenue by Segment (annual)
$11.97BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $12.00B | $3.95B | $15.46 |
| 2024 | $11.02B | $-535.60M | $-2.08 |
| 2023 | $9.87B | $3.62B | $14.05 |
| 2022 | $8.93B | $3.32B | $12.97 |
| 2021 | $7.57B | $2.34B | $9.09 |
| 2020 | $6.21B | $2.71B | $10.44 |
| 2019 | $4.16B | $1.18B | $4.58 |
| 2018 | $3.05B | $2.10B | $8.25 |
| 2017 | $2.49B | $263.48M | $1.06 |
| 2016 | $1.70B | $-112.05M | $-0.46 |
| 2015 | $1.03B | $-558.12M | $-2.32 |
| 2014 | $580.41M | $-738.55M | $-3.14 |
| 2013 | $1.21B | $-445.03M | $-1.98 |
| 2012 | $1.53B | $-107.03M | $-0.50 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $22.72
- Implied price
- $658.77
- Return from $515.02
- 5.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $327.53 — -36.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 25 | 29 | 33 | 37 |
|---|---|---|---|---|---|
| -2.0% | -10.6% | -7.5% | -4.7% | -2.2% | 0.1% |
| 3.0% | -6.1% | -2.7% | 0.2% | 2.8% | 5.2% |
| 8.0% | -1.5% | 2.0% | 5.0% | 7.8% | 10.3% |
| 13.0% | 3.0% | 6.7% | 9.9% | 12.8% | 15.4% |
| 18.0% | 7.6% | 11.4% | 14.8% | 17.8% | 20.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (67)
- News (RSS)fool·3d ago·Positive
2 Growth Stocks to Buy in November Without Any Hesitation Vertex and Regeneron started 2026 slowly, but blockbuster results and deep pipelines have both stocks climbing again.
View source ↗ - News (RSS)seekingalpha·5d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsseekingalpha.com·6d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript
View source ↗ - News (RSS)fool·9d ago·Positive
Amgen vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027? Amgen trades at a lower forward P/E than Vertex, but Vertex's near-zero debt and cystic fibrosis dominance make the trade-off harder to call.
View source ↗ - News (RSS)seekingalpha·9d ago·Neutral
Vertex Resource Group Q3 GAAP EPS of $0.01, revenue of $57.14M
View source ↗ - Newsdefenseworld.net·12d ago·Negative
Vertex Pharmaceuticals Incorporated $VRTX Stock Purchased by Allspring Global Investments Holdings LLC Allspring Global Investments Holdings LLC raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) by 11.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 157,086 shares of the pharmaceutical company's stock after purchasing an additional
View source ↗ - News (RSS)seekingalpha·17d ago·Neutral
Vertex Software: Lock In Gains On This Rebound (Rating Downgrade)
View source ↗ - Newszacks.com·19d ago·Negative
VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.
View source ↗ - News (RSS)seekingalpha·19d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 Earnings Call Transcript Vertex Pharmaceuticals Incorporated ( VRTX ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Duncan J. McKechnie - Executive VP & Chief Commercial Officer Charles Wagner - Executive VP, COO & CFO Conference Call Participants Cory Kasimov - Evercore ISI Institutional Equities, Research Division J…
View source ↗ - News (RSS)seekingalpha·19d ago·Neutral
Vertex raises 2026 revenue guidance following mixed Q3 results
View source ↗ - News (RSS)investing·20d ago·Neutral
Why is Vertex Pharmaceuticals stock climbing today?
View source ↗ - News (RSS)fool·20d ago·Positive
Vertex Spends Its CF Growth on New Launches: Rapid Earnings Reaction Vertex's cystic fibrosis business is still growing, but the company is pouring those gains into new franchises. Here's what the third quarter shows about the cost of building its next act.
View source ↗ - Newszacks.com·20d ago·Neutral
Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
View source ↗ - Newszacks.com·20d ago·Negative
Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings Estimates Vertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.76 per share, missing the Zacks Consensus Estimate of $4.92 per share. This compares to earnings of $4.8 per share a year ago.
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
Key Events This Week: Midterms, Jobs, Earnings, Central Banks And More Key Events This Week: Midterms, Jobs, Earnings, Central Banks And More Welcome to the first business day of November, and as DB's Jim Reid writes in his Morning Reid note, the week ahead is a big one in the US and with it for global markets, with tomorrow’s midterm elections and Friday’s October jobs report the obvious highlights, alongside the ISM surveys and Wednesday’s Treasury quarterly refunding announcement. Elsewhere,
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
Futures Rise As Oil Slides Below $100 On Trump Iran Diplomacy Report, Tech Bounces Ahead Of Midterms Futures Rise As Oil Slides Below $100 On Trump Iran Diplomacy Report, Tech Bounces Ahead Of Midterms US futures are higher as a slide in oil, a tentative tech rebound and some old-fashioned seasonality lift sentiment on the eve of the midterms: crude tumbled more than 4% after Axios reported that Trump told Netanyahu he wants to give diplomacy with Iran more time before resuming strikes, chips bo
View source ↗ - News (RSS)seekingalpha·21d ago·Neutral
Vertex Pharmaceuticals Q3 2026 Earnings Preview
View source ↗ - Newszacks.com·25d ago·Neutral
Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics Evaluate the expected performance of Vertex (VRTX) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
View source ↗ - Newszacks.com·25d ago·Neutral
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
View source ↗ - News (RSS)fool·26d ago·Negative
Amgen vs. Vertex Pharmaceuticals: Massive Pharmaceutical Scale vs. Steady Drug Revenue Amgen's quarterly revenue swings between $8.1B and $10.1B, while Vertex climbs steadily from $2.8B to $3.3B—a tale of scale versus trajectory.
View source ↗ - Newszacks.com·27d ago·Neutral
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.
View source ↗ - Newszacks.com·27d ago·Neutral
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - News (RSS)fool·29d ago·Neutral
Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Here's Why That's About to Change. Vertex is expanding beyond its cystic fibrosis franchise.
View source ↗ - News (RSS)seekingalpha·29d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript
View source ↗ - Newsseekingalpha.com·29d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript
View source ↗ - News (RSS)seekingalpha·29d ago·Neutral
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow
View source ↗ - News (Marketaux)seekingalpha.com·29d ago·Neutral
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow (NASDAQ:VRTX) 2026-10-23 Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow (NASDAQ:VRTX) 2026-10-23
View source ↗ - Newsbusinesswire.com·30d ago·Positive
…ngland Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an …
View source ↗ - News (RSS)fool·33d ago·Positive
AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin with concentrated cystic fibrosis exposure.
View source ↗ - Newszacks.com·33d ago·Positive
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.
View source ↗ - Newszacks.com·37d ago·Positive
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now? Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newszacks.com·38d ago·Negative
Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its last close.
View source ↗ - News (RSS)fool·38d ago·Neutral
Forget Cystic Fibrosis: Vertex's Next Growth Engine Could Be Hormone Disorders Vertex Pharmaceuticals is showing that it isn't a one-trick pony.
View source ↗ - 4chan /biz/biz·41d ago·Negative
>>62773351 gonna go condors on VRTX tomorrow, some others. Anyone here tracking MANE? Nuts volatility on it, I guess it's a hair loss company with a slow release minoxidil?
View source ↗ - News (RSS)seekingalpha·42d ago·Neutral
Vertex Built The NaV1.8 Market, Latigo May Be The One To Profit From It
View source ↗ - Newszacks.com·44d ago·Positive
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.
View source ↗ - Newszacks.com·48d ago·Neutral
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
View source ↗ - News (RSS)fool·49d ago·Positive
Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026? One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
View source ↗ - News (Marketaux)insidermonkey.com·50d ago·Positive
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets That makes Vertex Pharmaceu[+223 characters]
View source ↗ - Newszacks.com·52d ago·Neutral
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.
View source ↗ - 4chan /biz/biz·53d ago·Positive
…-IBM Corporation----IBM----Arvind Krishna----$207.26 Billion 10----T-Mobile US, Inc.----TMUS----Srinivasan Gopalan----$174.82 Billion 11----Vertex Pharmaceuticals----VRTX----Reshma Kewalramani----$133.74 Billion 12----Snowflake Inc.----SNOW----Sridhar Ramaswamy----$116.41 Billion 13----Adobe Inc.----ADBE----Shantanu Narayen----$90.75 Billion 14----Cadence Design Systems, Inc.----CDNS----Anirudh Devgan----$89.27 Billion 15----FedEx Corporation----FDX----Raj Subramaniam----$68.01 Billion 16----Fle…
View source ↗ - News (RSS)economictimes·53d ago·Neutral
Vertex in funding talks with RapidCanvas, Supernova
View source ↗ - News (RSS)seekingalpha·54d ago·Negative
Vertex Pharmaceuticals- Still Too Much Emphasis On CF Supremacy - I Foresee A Downgrade
View source ↗ - Newszacks.com·59d ago·Neutral
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.
View source ↗ - News (RSS)fool·59d ago·Positive
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
View source ↗ - Newszacks.com·61d ago·Neutral
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newszacks.com·65d ago·Positive
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's Why Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior day's close.
View source ↗ - News (RSS)financialpost·66d ago·Negative
Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan VANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Global Strategic Minerals Corp. (the “Vendor”), pursuant to which the Company will acquire (the “Transaction”) […]
View source ↗ - News (RSS)seekingalpha·69d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·72d ago·Neutral
Vertex Pharmaceuticals Incorporated (VRTX): Crinetics Acquisition Creates a New Growth Engine Beyond Cystic Fibrosis
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·73d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·73d ago·Positive
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)seekingalpha·74d ago·Neutral
Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution
View source ↗ - Newszacks.com·75d ago·Neutral
Vertex Pharmaceuticals (VRTX) Suffers a Larger Drop Than the General Market: Key Insights In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $528.9, indicating a -3.15% shift from the previous trading day.
View source ↗ - Newszacks.com·75d ago·Neutral
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - News (RSS)fool·79d ago·Positive
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? They could both outperform the market over the medium term, but one appears to have a clear edge.
View source ↗ - Newszacks.com·81d ago·Neutral
Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report? Vertex (VRTX) reported earnings 30 days ago. What's next for the stock?
View source ↗ - News (RSS)fool·92d ago·Positive
Vertex Pharmaceuticals: A Biotech Cash Cow With Pipeline Upside? Vertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.
View source ↗ - News (RSS)yahoo·94d ago·Positive
Are Wall Street Analysts Bullish on Vertex Stock?
View source ↗ - News (RSS)investing·95d ago·Neutral
Vertex Pharmaceuticals stock hits all-time high at 546.17 USD
View source ↗ - News (RSS)yahoo·99d ago·Neutral
Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?
View source ↗ - News (RSS)seekingalpha·100d ago·Positive
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)
View source ↗ - News (RSS)investing.com·104d ago·Neutral
Why is Vertex Pharmaceuticals stock surging today?
View source ↗ - News (Alpha Vantage)ETF Database·123d ago·Positive
T. Rowe Price's Love Says Small-Cap Earnings Are Turning Jodi Love, lead portfolio manager of the T. Rowe Price Small-Mid Cap ETF (TMSL), believes that small-cap earnings are turning around after 10 quarters of declines, with estimates now pointing to accelerating growth. She notes that small and mid-cap stocks are trading at a significant discount to large caps, offering substantial room for growth. Love's fund, TMSL, has seen strong performance and capitalizes on this shift by investing in "pi
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $4.20 per share
Typical surprise -0.2% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 2$4.76 vs $4.82miss
- Mon, Aug 3$4.73 vs $4.74miss
- Mon, May 4$4.47 vs $4.24beat
- Thu, Feb 12$5.03 vs $5.11miss
- Mon, Nov 3$4.80 vs $4.57beat
- Mon, Aug 4$4.52 vs $4.29beat
Estimates and results for VRTX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by VRTX officers and directors.
- Bought
- —
- Sold
- $64.5m
0 trades
50 trades
- Thornberry Nancysold
- Bhatia Sangeeta N.sold
- Wagner Charles F Jrsold
- Kewalramani Reshmasold
- Tatsis Ouraniasold
- Mckechnie Duncansold
- Liu Joysold
- Bozic Carmensold
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Buy$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Sep 7, 2026 (12d later)Sell$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Feb 3, 2026 (5d later)Sell$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Jan 13, 2026 (447d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (39d later)Buy$1,001 - $15,000
- David Taylorhouse · OH02 · disclosed Sep 3, 2025 (27d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (64d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (63d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (245d later)Buy$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Jun 23, 2025 (42d later)Sell$15,001 - $50,000
- Byron Donaldshouse · FL19 · disclosed Apr 15, 2025 (26d later)Sell$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed Apr 15, 2025 (26d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed Apr 14, 2025 (32d later)Buy$15,001 - $50,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
